Related Experiment Video
Updated: Jun 29, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Increased serum soluble OX40 in patients with systemic sclerosis
Kazuhiro Komura1, Ayumi Yoshizaki, Masanari Kodera
1Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
The Journal of Rheumatology
|October 10, 2008
Summary
Serum soluble OX40 (CD134) levels are elevated in patients with early systemic sclerosis (SSc). This finding suggests a correlation between soluble OX40 and the initial stages of SSc disease.
Area of Science:
- Immunology
- Rheumatology
Background:
- Systemic sclerosis (SSc) is a complex autoimmune disease.
- The tumor necrosis factor receptor superfamily plays a role in immune regulation.
Purpose of the Study:
- To measure serum soluble OX40 (CD134) levels in SSc patients.
- To investigate the clinical associations of soluble OX40 in SSc.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) was used to quantify serum soluble OX40.
- Study included 53 SSc patients, 15 systemic lupus erythematosus (SLE) patients, and 32 healthy controls.
Main Results:
- Soluble OX40 levels were significantly higher in SSc patients compared to SLE patients and healthy controls.
- Elevated soluble OX40 levels were associated with a disease duration of less than two years.
Conclusions:
- Serum soluble OX40 levels are elevated in patients with systemic sclerosis.
- These elevated levels correlate with early-onset SSc, suggesting a role in disease pathogenesis.